Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer

NCT00067548 ·Status: COMPLETED ·Phase: PHASE2

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

NCT02087423 ·Status: COMPLETED ·Phase: PHASE2

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

NCT03727477 ·Status: COMPLETED

Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC

NCT02047344 ·Status: COMPLETED ·Phase: PHASE2

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

NCT00047840 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

NCT06378892 ·Status: RECRUITING ·Phase: PHASE2

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

NCT04362072 ·Status: COMPLETED ·Phase: PHASE4

TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00036920 ·Status: COMPLETED ·Phase: PHASE2

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT00932893 ·Status: COMPLETED ·Phase: PHASE3

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

NCT02393625 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

NCT05950139 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

NCT03739710 ·Status: COMPLETED ·Phase: PHASE2

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

NCT05200481 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer

NCT00047801 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer

NCT00104754 ·Status: WITHDRAWN ·Phase: PHASE2

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

NCT01970865 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

NCT05142696 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

NCT05800587 ·Status: RECRUITING ·Phase: PHASE2

Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer

NCT04164745 ·Status: UNKNOWN ·Phase: PHASE2

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

NCT01441128 ·Status: TERMINATED ·Phase: PHASE1

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

NCT06780085 ·Status: RECRUITING ·Phase: PHASE2

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

NCT05553808 ·Status: COMPLETED ·Phase: PHASE2

Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

NCT05257512 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

NCT01362296 ·Status: COMPLETED ·Phase: PHASE2